Intrinsic Obstacles to Human Immunodeficiency Virus Type 1 Coreceptor Switching
暂无分享,去创建一个
[1] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[2] G. Simmons,et al. T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism. , 2000, The Journal of general virology.
[3] C. Kuiken,et al. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period , 1995, Journal of virology.
[4] M. Malim,et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.
[5] D. Ho,et al. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals , 1993, Journal of virology.
[6] H. Schuitemaker,et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.
[7] N. Michael,et al. Relationship between V3 genotype, biologic phenotype, tropism, and coreceptor use for primary isolates of human immunodeficiency virus type 1. , 2001, Journal of human virology.
[8] M. Malim,et al. DNA Deamination Mediates Innate Immunity to Retroviral Infection , 2003, Cell.
[9] H. Schuitemaker,et al. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture , 1991, Journal of virology.
[10] M. Cho,et al. N-Linked Glycosylation Sites Adjacent to and within the V1/V2 and the V3 Loops of Dualtropic Human Immunodeficiency Virus Type 1 Isolate DH12 gp120 Affect Coreceptor Usage and Cellular Tropism , 2001, Journal of Virology.
[11] L. M. Mansky,et al. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.
[12] Rami Kantor,et al. High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment , 2003, Journal of Virology.
[13] A. Trkola,et al. Human Immunodeficiency Virus Type 1 Fitness Is a Determining Factor in Viral Rebound and Set Point in Chronic Infection , 2003 .
[14] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[15] J. Goudsmit,et al. ASSOCIATION BETWEEN BIOLOGICAL PROPERTIES OF HUMAN IMMUNODEFICIENCY VIRUS VARIANTS AND RISK FOR AIDS AND AIDS MORTALITY , 1989, The Lancet.
[16] Paul E. Kennedy,et al. HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.
[17] J. Albert,et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.
[18] D. Richman,et al. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. , 1993, The Journal of infectious diseases.
[19] Dan R. Littman,et al. Use of Coreceptors Other Than CCR5 by Non-Syncytium-Inducing Adult and Pediatric Isolates of Human Immunodeficiency Virus Type 1 Is Rare In Vitro , 1998, Journal of Virology.
[20] R. Swanstrom,et al. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. , 2001, Virology.
[21] P. Vernazza,et al. Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.
[22] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.
[23] A. Trkola,et al. Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.
[24] J. Barretina,et al. Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists , 2003, Antiviral therapy.
[25] Shannon M. Anderson,et al. Germinal Center Initiation, Variable Gene Region Hypermutation, and Mutant B Cell Selection without Detectable Immune Complexes on Follicular Dendritic Cells , 2000, The Journal of experimental medicine.
[26] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[27] Noah G. Hoffman,et al. Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.
[28] J. Margolick,et al. Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.
[29] Robert Blumenthal,et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] Marc Parmentier,et al. A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.
[31] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[32] E. De Clercq,et al. Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4 , 1999, Journal of Virology.
[33] E. De Clercq,et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 , 1994, Antimicrobial Agents and Chemotherapy.
[34] A. Trkola,et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[35] C. Cheng‐Mayer,et al. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Collman,et al. CXCR-4 Is Expressed by Primary Macrophages and Supports CCR5-Independent Infection by Dual-Tropic but Not T-Tropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[37] C. Cheng‐Mayer,et al. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. , 1995, Virology.
[38] A. Cann,et al. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism , 1993, Journal of virology.
[39] C. Cheng‐Mayer,et al. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation , 1990, Journal of virology.
[40] Gersende Caron,et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.
[41] F. McCutchan,et al. Human Immunodeficiency Virus Type 1 DNA Sequences Genetically Damaged by Hypermutation Are Often Abundant in Patient Peripheral Blood Mononuclear Cells and May Be Generated during Near-Simultaneous Infection and Activation of CD4+ T Cells , 2001, Journal of Virology.
[42] V. Trouplin,et al. Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors , 2003, Journal of Virology.
[43] L. Loeb,et al. Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV-1 env gene. , 1994, Virology.
[44] H. Schuitemaker,et al. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. , 2000, The Journal of clinical investigation.
[45] F. Galimi,et al. Two Mechanisms for Human Immunodeficiency Virus Type 1 Inhibition by N-Terminal Modifications of RANTES , 2003, Antimicrobial Agents and Chemotherapy.
[46] B. Berkhout,et al. Codon and amino acid usage in retroviral genomes is consistent with virus-specific nucleotide pressure. , 2002, AIDS research and human retroviruses.
[47] J. Phair,et al. Chemokine Coreceptor Usage by Diverse Primary Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[48] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[49] D. Nickle,et al. Selection for Human Immunodeficiency Virus Type 1 Recombinants in a Patient with Rapid Progression to AIDS , 2002, Journal of Virology.
[50] B. Chesebro,et al. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes , 1996, Journal of virology.
[51] Pascal Poignard,et al. Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.
[52] C. Cheng‐Mayer,et al. CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[53] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[54] Simon D W Frost,et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.